Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
BiVictriX Therapeutics PLC
BVXBiVictriX Therapeutics plc, a biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. The company develops Bi-Cygni, a proprietary platform that combines the discovery of novel, cancer-selective twin-antigen pairs or fingerprints with bispecific antibody engineering insights to create anti-cancer therapeutics. Its lead program is BVX001, a first-in-class Bi Cygni antibody drug conjugates to treat acute myeloid leukemia. The company also develops BVX002 for treating ovarian and other solid tumors; and BVX003 for bladder and other solid tumors. The company was formerly known as BiVictriX plc and changed its name to BiVictriX Therapeutics plc in August 2021. BiVictriX Therapeutics plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom. Address: Mereside, Macclesfield, United Kingdom, SK10 4TG
Analytics
Objectif de Cours de WallStreet
5 099 GBXRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés BVX
Analyse des dividendes BVX
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes BVX
Valorisation des titres BVX
financières BVX
Résultats | 2019 | Dynamique |